Allergy Therapeutics plc Receivables

The latest receivables for AGY.L is $11M as of December 2025. That compares with $8.6M in the prior-year period — up 27.5% year over year. Investors often review this figure alongside Allergy Therapeutics plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGY.L's receivables moved from $8.6M to $11M — a 27.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Allergy Therapeutics plc's operating scale or balance-sheet position.

A receivables figure of $11M for AGY.L is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AGY.L's receivables ($11M), review year-over-year change from $8.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.